The UK Health Security Agency (UKHSA) has started publishing regular technical briefings on the development and effectiveness of therapeutics used to treat patients with COVID-19 in the UK.
Thanks to the success of the vaccination programme, the number of people in hospital or suffering from severe disease has been greatly reduced. There are a number of effective therapeutics in use in the UK to treat those who still encounter serious illness as a result of COVID-19.
The surveillance programme to support the rollout of novel therapeutics will examine the level of access to various treatments, the extent to which emerging mutations and variants may affect efficacy, and the ongoing picture of clinical outcomes.
Updates and early data will be published regularly.